Form 8-K - Current report:
SEC Accession No. 0001193125-25-137119
Filing Date
2025-06-06
Accepted
2025-06-06 16:35:38
Documents
13
Period of Report
2025-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d933201d8k.htm   iXBRL 8-K 54209
  Complete submission text file 0001193125-25-137119.txt   204802

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nams-20250604.xsd EX-101.SCH 3567
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nams-20250604_def.xml EX-101.DEF 13771
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nams-20250604_lab.xml EX-101.LAB 22355
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nams-20250604_pre.xml EX-101.PRE 14559
15 EXTRACTED XBRL INSTANCE DOCUMENT d933201d8k_htm.xml XML 5726
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41562 | Film No.: 251031283
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)